EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
176 hedge funds and large institutions have $802M invested in Eagle Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 55 increasing their positions, 73 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
176
Holders Change
-7
Holders Change %
-3.83%
% of All Funds
3.48%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
16
Increased
55
Reduced
73
Closed
17
Calls
$15.4M
Puts
$5.04M
Net Calls
+$10.4M
Net Calls Change
+$8.16M
Top Buyers
| 1 |
WG
Winton Group
London,
United Kingdom
|
+$8.88M |
| 2 |
Renaissance Technologies
New York
|
+$7.23M |
| 3 |
BlackRock
New York
|
+$4.97M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$4.72M |
| 5 |
Goldman Sachs
New York
|
+$4.22M |
Top Sellers
| 1 |
HEC
Hudson Executive Capital
New York
|
-$8.92M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
-$5.55M |
| 3 |
MCM
Matarin Capital Management
New York
|
-$4.49M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.93M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$2.92M |
